Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0787
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2613
    -0.0009 (-0.07%)
     
  • USD/JPY

    151.2830
    -0.0890 (-0.06%)
     
  • Bitcoin USD

    70,074.01
    -470.19 (-0.67%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

NanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19

  • NanoViricides Inc (NYSE: NNVC) has reported data from animal studies evaluating its broad-spectrum antiviral drug candidate NV-CoV-2 to treat COVID-19 infections.

  • The treatment candidate was well tolerated in safety pharmacology studies in both rat and non-human primate models. Multiple injections of NV-CoV-2 were also well-tolerated in an extensive non-GLP study in rats performed by AR Biosystems Inc.

  • The studies showed that intravenous (IV) administration of NV-CoV-2 at doses of 25, 50, and 100 mg/kg did not affect rats' respiratory function. IV infusion at 25, 37.5, and 50 mg/kg did not have any toxicologic effects on cardiac rhythm or ECG morphology in cynomolgus monkeys. No significant effects on blood pressure and heart rate were observed.

  • Pre-IND application submission to the US FDA is up next to obtain guidance regarding human clinical trials.

  • Price Action: NNVC gained 6.8% at $5.03 in premarket trading on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement